Thermo Fisher Scientific (TMO)
Life-science tools and services; large-deal and bolt-on acquirer. Thermo Fisher Scientific is listed on the New York Stock Exchange and reports in USD. compounders.ai reads its annual filings and shows reported operating profit next to normalized EBITA under one published rulebook, every figure linked to the filing it was read from.
- Archetype
- US industrial acquirer
- Listing
- New York Stock Exchange: TMO (listing key
NYSE-TMO) - Country
- United States
- Reporting currency
- USD
- Filing source
- SEC inline XBRL (native)
- Latest filing on record
- Form 10-K for the fiscal year ended 2025-12-31 — Thermo Fisher Scientific, filed 26 Feb 2026 (25 filings on record)
- Fiscal years published
- FY2010–FY2025
- Normalized EBITA published
- Not yet
Key figures, FY2025
Fiscal year ended 31 Dec 2025, in USD as reported. Published 20 Oct 2026 under ruleset 1.4.0; read for this page on 20 Oct 2026. Each figure links to the filing it was read from; a computed figure links to its primary citation.
| Figure | FY2025 | Source |
|---|---|---|
| Income statement | ||
| Revenue | USD 44,556 million | Form 10-K for the fiscal year ended 2025-12-31 — Thermo Fisher Scientific · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · as filed |
| Reported operating profit | USD 7,746 million | Form 10-K for the fiscal year ended 2025-12-31 — Thermo Fisher Scientific · us-gaap:OperatingIncomeLoss · as filed |
| Reported operating margin | 17.4% | Form 10-K for the fiscal year ended 2025-12-31 — Thermo Fisher Scientific · us-gaap:OperatingIncomeLoss · computed from cited lines |
| Normalized EBITA | Not published for FY2025 | |
| Normalized EBITA margin | Not published for FY2025 | |
| Normalized EBITDA | Not published for FY2025 | |
| Returns on capital | ||
| ROIC incl. goodwill | Not published for FY2025 | |
| ROIC excl. goodwill | Not published for FY2025 | |
| ROIIC, 3 years | Not published for FY2025 | |
| Balance sheet and cash | ||
| Net debt | USD 29,533 million | Form 10-K for the fiscal year ended 2025-12-31 — Thermo Fisher Scientific · us-gaap:LongTermDebtAndCapitalLeaseObligations · computed from cited lines |
| Net debt to EBITDA | 2.81x | Form 10-K for the fiscal year ended 2025-12-31 — Thermo Fisher Scientific · us-gaap:LongTermDebtAndCapitalLeaseObligations · computed from cited lines |
| FCF before acquisitions | Not published for FY2025 | |
| FCF available to shareholders (FCFA2S) | Not published for FY2025 | |
Earlier years (FY2010–FY2024) are in the terminal's tabs below.
In the terminal
- Thermo Fisher Scientific: Financials
- Thermo Fisher Scientific: Normalization
- Thermo Fisher Scientific: Growth
- Thermo Fisher Scientific: KPIs
- Thermo Fisher Scientific: Returns
- Thermo Fisher Scientific: Sources
How the figures are made: methodology · glossary · how to cite them: citation guidelines.